BPS2025 - The role of reversible protein-protein interactions in the biophysical profile of novel monoclonal antibody therapies
Jack Maurer(University of Oregon), Kristina Zick(Johnson & Johnson (United States)), Peyton B. Randolph(Broad Institute)
Cited by 0
Related Papers
Engineered pegRNAs improve prime editing efficiency
|Nature Biotechnology|2021|747
Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins
|Cell|2022|656
Continuous evolution of SpCas9 variants compatible with non-G PAMs
|Nature Biotechnology|2020|361